Abstract
The comprehensive genomic profiling (CGP) diagnosis initially designed for targeted therapy is finding its way in cancer therapy with immune checkpoint inhibitors. Besides the utility of identifying targets for precision therapy, CGP also measures the tumor mutational burden (TMB) and the microsatellite instability status (MSI), which both are associated with the response to PD-1 blockade immunotherapy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
